Oncosuppressor-Mutated Cells as a Liquid Biopsy Test for Cancer-Screening.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 02 2019
20 02 2019
Historique:
received:
26
06
2018
accepted:
18
12
2018
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
15
9
2020
Statut:
epublish
Résumé
We reported on the ability of immortalized or oncosuppressor-mutated cells (OMCs) to uptake circulating cancer-factors and give tumors when transplanted into mice. This led to the first biological based liquid biopsy test, which we called MATER-D platform. In the present study, we showed for the first time that a different type of OMCs (PTEN-deficient human epithelial MCF10A cells) turn malignant when exposed to cancer patient's sera, confirming the concept that different cells with diverse oncosuppressor mutations can uptake cancer factors and be used in biological based liquid biopsy tests. Our observations were confirmed in a large variety of solid and haematological malignancies. This test was able to detect dysplasia and carcinomas in situ lesions in different organs and circulating factors in cancer patients years after the removal of their lesions. To our knowledge, this ability is unique and not shared by other liquid biopsy platforms. Immunohistochemistry analysis of the xenotransplants revealed identical patterns of differentiation regardless of the cancer type, showing that differentiation through horizontal transfer might be dependent on the nature of the target cells rather than the type of cancer factors. These data strengthen the notion that OMC-based liquid biopsy tests might be promising platforms for cancer screening.
Identifiants
pubmed: 30787346
doi: 10.1038/s41598-019-38736-y
pii: 10.1038/s41598-019-38736-y
pmc: PMC6382857
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2384Références
Histol Histopathol. 1999 Oct;14(4):1159-64
pubmed: 10506932
J Immunol. 2001 Jan 15;166(2):868-76
pubmed: 11145662
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6407-11
pubmed: 11353826
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Mod Pathol. 2006 Apr;19(4):533-40
pubmed: 16474379
Carcinogenesis. 2007 Jul;28(7):1379-86
pubmed: 17341655
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Blood. 2007 Nov 1;110(9):3234-44
pubmed: 17666571
Int J Colorectal Dis. 2009 Apr;24(4):369-75
pubmed: 18797888
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Cancer Res. 1990 Sep 15;50(18):6075-86
pubmed: 1975513
Cancer Res. 2009 Nov 1;69(21):8275-83
pubmed: 19843859
Cancer Res. 2010 Jan 15;70(2):560-7
pubmed: 20068178
FASEB J. 2010 Jun;24(6):1838-51
pubmed: 20097873
Lab Invest. 2010 Nov;90(11):1549-57
pubmed: 20805791
Semin Immunopathol. 2011 Sep;33(5):419-40
pubmed: 21174094
Nat Commun. 2011 Feb 01;2:180
pubmed: 21285958
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Med Hypotheses. 2013 Jan;80(1):75-82
pubmed: 23177570
PLoS One. 2012;7(12):e52754
pubmed: 23285175
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
Front Pharmacol. 2013 Mar 06;4:21
pubmed: 23508692
Transl Res. 2014 Apr;163(4):286-95
pubmed: 24231336
World J Surg Oncol. 2014 Mar 28;12:73
pubmed: 24678904
Cancer Discov. 2014 Jun;4(6):650-61
pubmed: 24801577
Adv Biol Regul. 2014 Sep;56:66-80
pubmed: 25088603
J Exp Clin Cancer Res. 2014 Sep 30;33:86
pubmed: 25266310
Cancer Cell. 2014 Nov 10;26(5):707-21
pubmed: 25446899
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
PLoS One. 2015 Jul 06;10(7):e0131285
pubmed: 26147507
Oncotarget. 2015 Nov 3;6(34):35231-46
pubmed: 26497685
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
J Exp Clin Cancer Res. 2016 May 14;35:80
pubmed: 27179759
Cancer Genomics Proteomics. 2017 01-02;14(1):1-15
pubmed: 28031234
Med Hypotheses. 2017 Mar;100:82-86
pubmed: 28236854
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Arch Pathol Lab Med. 2017 Sep;141(9):1155-1180
pubmed: 28854347
J Exp Clin Cancer Res. 2017 Aug 30;36(1):113
pubmed: 28854931
J Circ Biomark. 2016 Nov 4;5:1849454416663661
pubmed: 28936263
BMC Cancer. 2017 Oct 23;17(1):697
pubmed: 29061138
Nat Commun. 2017 Nov 6;8(1):1319
pubmed: 29105655
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Nature. 1983 Aug 18-24;304(5927):596-602
pubmed: 6308472